Fig. 5: Anti-SETDB1 therapy reduces metastatic uveal melanoma cell proliferation and survival. | Cell Death & Disease

Fig. 5: Anti-SETDB1 therapy reduces metastatic uveal melanoma cell proliferation and survival.

From: SETDB1 is critically required for uveal melanoma growth and represents a promising therapeutic target

Fig. 5

A OMM1.3, OMM2.5, and OMM1 metastatic uveal melanoma cells were seeded at low density and cultured for 96 h in absence or presence of increasing concentration of Mithramycin A. Representative images of three independent experiments are shown. B Immunoblot analysis of metastatic uveal melanoma cells exposed to Mithramycin A (15 and 30 nM) for 72 h with the indicated antibodies. HSP90 was used as a loading control. C Immunoblot to cleaved PARP in control OMM1.3 cells and OMM1.3 cells treated with Mithramycin A (15 and 30 nM) for 72 h. β-Actin was used as a loading control. D Analysis of apoptosis in control OMM1.3 cells and OMM1.3 cells treated with Mithramycin A at the indicated concentrations for 96 h. Annexin V diagram and quantification of the percentage of late apoptotic cells using the Annexin V assay, n = 3. p-value was derived from Welch’s t-test. *p = 0.0399.

Back to article page